Diabetes Drug May Be Linked With An Increased Rate of Death

A review by the U.S. Food and Drug Administration (FDA) has found that the AstraZeneca Plc’s diabetes drug, Onglyza, may be associated with an increased rate of death.

A trial was underway of more than 16,000 patients taking Onglyza. It has been reported that these patients had an increased risk of hospital visits due to heart failure.

The personal injury attorneys at Williams DeClark Tuschman will continue to monitor this as more news unfolds. In the mean time, should you have any questions regarding Onglyza, please call our office at 419-318-0772. We are more than happy to answer any questions you have.


Schedule Your Free Consultation

Consultations are provided free of charge, so take this chance to get answers to your questions, straight from a team of experienced and trusted advocates. We are ready to serve you.

    • Please enter your name.
    • This isn't a valid phone number.
      Please enter your phone number.
    • This isn't a valid email address.
      Please enter your email address.
    • Please make a selection.
    • Please enter a message.